Loading
A phase 2 trial of SHR-A2102, Adebrelimab, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07229729 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 300 participants planned, started 2025-11-24 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102, Adebrelimab, Paclitaxel, Carboplatin, Alomnertinib Mesilate. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Resectable stage I to III non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.